Freenome
company on 4 shows · 10 statements across 5 episodes · said 35 times in 13 episodes since 2017
the a16z Podcast 24 
the MAD Podcast 8 
20VC 2 
Capital Allocators 1
Mentions by year, every show
tap a year for its mentions
the a16z Podcast 24the MAD Podcast 820VC 2Capital Allocators 1
2022 2 mentions in 1 episode
2020 1 mention in 1 episode
2019 11 mentions in 6 episodes 2 per episode
- a16z Podcast | Revisiting the Gene
- a16z Podcast | Taking the Pulse on Bio
- a16z Podcast | When Will Genomics Live Up to the Hype?
- a16z Podcast | On the Genomics of Disease, From Science to Business
- AI is Industrializing Discovery
- Scott Kupor - Andreessen Horowitz (First Meeting EP.07)
- every mention in 2019, scene by scene →
2018 10 mentions in 2 episodes 5 per episode
2017 11 mentions in 3 episodes 4 per episode
every mention on every show, scene by scene, with the transcript →
10 statements about Freenome, every show
Cathie Wood: ARK holds private molecular diagnostics startup Freenome
“And I'll also say that in the private world, we think a contender is Freenome. And we have that as one of our first holdings.”
Freenome detects dynamic cell-free DNA from circulating immune cells
“What we're detecting is DNA fragments that are actually coming from the immune cells that are turning over in your body.”
Ott: Dynamic DNA testing will enable detection of any disease with immune changes
“The underlying biology should theoretically enable us to detect any diseases where there is an immune change.”
AI diagnostics can continuously improve accuracy post-launch by learning from results
“Because we can now make a diagnostic that's fundamentally AI-based, even after we launch the test into the market, we can actually work with our partners to get results of the test that we sell back so that we can teach the artificial intelligence that it made…”
Pande: AI cancer detection startup Freenome achieves over 90% accuracy
“Companies like Freenome that look for the signals for cancer from blood can do considerably better. You know, 90% and plus.”
Pande: BioAge uses machine learning on young blood to develop anti-aging therapeutics
“And so if you think about the game plan that Freenome runs for taking blood and understanding where there's cancer and what's the cancerous agents in there, what BioAge is doing is doing essentially the same thing, looking at the blood of young, using machine …”
Chen: Freenome is developing a cell-free DNA blood test for cancer diagnosis
“The company Freenome is working on a cancer diagnostic by reading the DNA that's free floating in your bloodstream.”
Pande: Freenome's genomic ML will drive cancer cure rates to 80-100%
“So a company like Freenome will use machine learning and deep learning with genomics to be able to tell whether you have cancer early enough, such that the cure rate, success rate could be 80%, a hundred percent.”
Pande: Digital health startups could be acquired by pharma or tech giants
“I could see a Pfizer buying Omada, you know, and maybe coupling with a drug or maybe not. I could see Google buying a company like Omada. I could see Freenome being bought either by a therapeutics company that wants a diagnostic, or by, let's say, a sequencing…”
Pande: Freenome's test will cost about as much as a dental visit
“Freenome's test that's something that you could do once a year, you could do twice a year, it's comparable to the cost of the dentist, and something where one could catch cancer immediately, like catching a cavity at a very early stage, and it gets cured, and …”